Skip to main content

Advertisement

Table 1 Baseline characteristics

From: Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy

Characteristics Total (N = 87) TGF-β WT (N = 66) TGF-β MT (N = 21) P-Value
Age Median (range) 59 (31–75) 61 (38–75) 54 (31–74) 0.020
Sex Male 50 (57.5%) 36 (54.4%) 14 (66.7%) 0.33
  Female 37 (42.5%) 30 (45.5%) 7 (33.3%)  
Location Proximal 28 (32.2%) 19 (28.8%) 9 (42.9%) 0.23
  Distal 59 (67.8%) 47 (71.2%) 12 (57.1%)  
Stage II, high-risk 14 (16.1%) 8 (12.1%) 6 (28.6%) 0.074
  III 73 (83.9%) 58 (87.9%) 15 (71.4%)  
T stage 1 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.41
  2 1 (1.1%) 1 (1.5%) 0 (0.0%)  
  3 62 (71.3%) 49 (74.2%) 13 (61.9%)  
  4 24 (27.6%) 16 (24.2%) 8 (38.1%)  
N stage 0 14 (16.1%) 8 (12.1%) 6 (28.6%) 0.18
  1 29 (33.3%) 24 (36.4%) 5 (23.8%)  
  2 44 (50.6%) 34 (51.5%) 10 (47.6%)  
Histology Non-MAC 78 (89.7%) 65 (98.5%) 13 (61.9%) < 0.001
  MAC 9 (10.3%) 1 (1.5%) 8 (38.1%)  
MSI MSS/MSI-L 83 (96.5%) 65 (100.0%) 18 (85.7%) 0.013
  MSI-H 3 (3.5%) 0 (0.0%) 3 (14.3%)  
Time to recurrence < 1 year 19 (21.8%) 11 (16.7%) 8 (38.1%) 0.038
≥1 year 68 (78.2%) 55 (83.3%) 13 (61.9%)  
Curative resection after distant recurrence Not done 52 (59.8%) 39 (59.1%) 13 (61.9%) 0.82
Done 35 (40.2%) 27 (40.9%) 8 (38.1%)  
  1. Abbreviations: MAC mucinous adenocarcinoma, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high